Free Trial
NASDAQ:BGLC

BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

BioNexus Gene Lab logo
$0.77 -0.05 (-6.58%)
As of 11:01 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About BioNexus Gene Lab Stock (NASDAQ:BGLC)

Advanced

Key Stats

Today's Range
$0.82
▼
$0.82
50-Day Range
$0.81
▼
$1.61
52-Week Range
$0.81
▼
$4.97
Volume
429 shs
Average Volume
38,324 shs
Market Capitalization
$2.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making.

The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications.

BioNexus Gene Lab’s operations are primarily based in Malaysia. The company’s activities combine diagnostic testing services with the distribution of chemicals to commercial customers.

AI Generated. May Contain Errors.

BioNexus Gene Lab Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

BGLC MarketRank™: 
1.09096945551 of 5 stars

BioNexus Gene Lab scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNexus Gene Lab has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    BioNexus Gene Lab has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioNexus Gene Lab's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNexus Gene Lab is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNexus Gene Lab is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNexus Gene Lab has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.11% of the float of BioNexus Gene Lab has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNexus Gene Lab has a short interest ratio ("days to cover") of 0.96, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNexus Gene Lab has recently decreased by 64.87%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioNexus Gene Lab does not currently pay a dividend.

  • Dividend Growth

    BioNexus Gene Lab does not have a long track record of dividend growth.

  • News Sentiment

    BioNexus Gene Lab has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Industrials companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for BioNexus Gene Lab this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.05% of the stock of BioNexus Gene Lab is held by insiders.

  • Percentage Held by Institutions

    18.85% of the stock of BioNexus Gene Lab is held by institutions.

  • Read more about BioNexus Gene Lab's insider trading history.
Receive BGLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BGLC Stock News Headlines

BioNexus Gene Lab (NASDAQ:BGLC) Shares Up 7.5% - Should You Buy?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

BGLC Stock Analysis - Frequently Asked Questions

BioNexus Gene Lab's stock was trading at $4.1150 at the beginning of 2026. Since then, BGLC shares have decreased by 80.0% and is now trading at $0.8210.

BioNexus Gene Lab Corp. (NASDAQ:BGLC) posted its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.52) EPS for the quarter. The company had revenue of $483.76 thousand for the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative trailing twelve-month return on equity of 32.92%.

BioNexus Gene Lab's stock reverse split before market open on Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

BioNexus Gene Lab (BGLC) raised $5 million in an IPO on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO.

Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Trading Companies & Distributors
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:BGLC
CIK
1737523
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.98 million
Net Margins
-82.38%
Pretax Margin
-82.38%
Return on Equity
-32.92%
Return on Assets
-29.75%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
6.08
Quick Ratio
5.28

Sales & Book Value

Annual Sales
$3.13 million
Price / Sales
0.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.56 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
2,933,000
Free Float
2,932,000
Market Cap
$2.25 million
Optionable
Not Optionable
Beta
4.28
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:BGLC) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners